Radioimmunotherapy and secondary leukemia: A case report

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

This study describes a patient with a relapsed, diffuse, large B cell lymphoma (DLBCL) treated with radioimmunotherapy (RIT) with yttrium-90 (90Y)-ibritumomab tiuxetan (Zevalin®) who 5 months later developed acute myeloid leukemia (AML) with inversion of chromosome 16. Our data indicate that molecular biological techniques should be used in selected cases to integrate data obtained with standard cytogenetics: using RT-PCR we showed that inversion of chromosome 16 was already present before RIT, in striking contrast to the normal karyotype found with conventional cytogenetics. This approach will allow investigators to avoid misleading data and provide support for conclusions regarding the side effects of treatment.

Original languageEnglish
JournalLeukemia Research
Volume34
Issue number1
DOIs
Publication statusPublished - Jan 2010

Fingerprint

Radioimmunotherapy
Chromosomes, Human, Pair 16
Cytogenetics
Leukemia
Lymphoma, Large B-Cell, Diffuse
Karyotype
Acute Myeloid Leukemia
Research Personnel
Polymerase Chain Reaction
ibritumomab tiuxetan
Therapeutics

Keywords

  • Acute leukemia
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

@article{28587740999142e9983570ba6c9b63eb,
title = "Radioimmunotherapy and secondary leukemia: A case report",
abstract = "This study describes a patient with a relapsed, diffuse, large B cell lymphoma (DLBCL) treated with radioimmunotherapy (RIT) with yttrium-90 (90Y)-ibritumomab tiuxetan (Zevalin{\circledR}) who 5 months later developed acute myeloid leukemia (AML) with inversion of chromosome 16. Our data indicate that molecular biological techniques should be used in selected cases to integrate data obtained with standard cytogenetics: using RT-PCR we showed that inversion of chromosome 16 was already present before RIT, in striking contrast to the normal karyotype found with conventional cytogenetics. This approach will allow investigators to avoid misleading data and provide support for conclusions regarding the side effects of treatment.",
keywords = "Acute leukemia, Radioimmunotherapy",
author = "Michele Magni and {Di Nicola}, Massimo and Adele Testi and Antonello Cabras and Liliana Devizzi and Anna Guidetti and Paola Matteucci and Simonetta Viviani and Valeria Bonfante and Cristiana Carniti and Irene Ricca and Antonino Carbone and Carmelo Carlo-Stella and Gianni, {Alessandro M.}",
year = "2010",
month = "1",
doi = "10.1016/j.leukres.2009.04.028",
language = "English",
volume = "34",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Ltd",
number = "1",

}

TY - JOUR

T1 - Radioimmunotherapy and secondary leukemia

T2 - A case report

AU - Magni, Michele

AU - Di Nicola, Massimo

AU - Testi, Adele

AU - Cabras, Antonello

AU - Devizzi, Liliana

AU - Guidetti, Anna

AU - Matteucci, Paola

AU - Viviani, Simonetta

AU - Bonfante, Valeria

AU - Carniti, Cristiana

AU - Ricca, Irene

AU - Carbone, Antonino

AU - Carlo-Stella, Carmelo

AU - Gianni, Alessandro M.

PY - 2010/1

Y1 - 2010/1

N2 - This study describes a patient with a relapsed, diffuse, large B cell lymphoma (DLBCL) treated with radioimmunotherapy (RIT) with yttrium-90 (90Y)-ibritumomab tiuxetan (Zevalin®) who 5 months later developed acute myeloid leukemia (AML) with inversion of chromosome 16. Our data indicate that molecular biological techniques should be used in selected cases to integrate data obtained with standard cytogenetics: using RT-PCR we showed that inversion of chromosome 16 was already present before RIT, in striking contrast to the normal karyotype found with conventional cytogenetics. This approach will allow investigators to avoid misleading data and provide support for conclusions regarding the side effects of treatment.

AB - This study describes a patient with a relapsed, diffuse, large B cell lymphoma (DLBCL) treated with radioimmunotherapy (RIT) with yttrium-90 (90Y)-ibritumomab tiuxetan (Zevalin®) who 5 months later developed acute myeloid leukemia (AML) with inversion of chromosome 16. Our data indicate that molecular biological techniques should be used in selected cases to integrate data obtained with standard cytogenetics: using RT-PCR we showed that inversion of chromosome 16 was already present before RIT, in striking contrast to the normal karyotype found with conventional cytogenetics. This approach will allow investigators to avoid misleading data and provide support for conclusions regarding the side effects of treatment.

KW - Acute leukemia

KW - Radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=73249153258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73249153258&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2009.04.028

DO - 10.1016/j.leukres.2009.04.028

M3 - Article

C2 - 19446876

AN - SCOPUS:73249153258

VL - 34

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 1

ER -